Search
for
Sort by
Research
30-60 / 1000+ resultsresearch Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat.
Terbinafine quickly builds up in skin and hair, staying effective for over 3 weeks.
research Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride
Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.